Search for a trial

A randomized, double-blind, repeat dose cross-over study
to assess the bronchodilator effects of once daily QVM149
following morning or evening dosing for 14 days compared
to placebo in patients with asthma

To investigate the potential influence of time of dosing (morning or evening)on the bronchodilator effect of once daily orally inhaled QVM149 compared toplacebo.

Randomized, double-blind, placebo-controlled oxytocin trial in children with Prader-Willi syndrome.
Effects on social behaviour.

To evaluate the effects of intranasal oxytocin versus placebo on social behaviour and also on eating behaviour in children with PWS.

Genistein as an add-on treatment for CF?

Our primary objective is to investigate whether a further gain in efficacy of oral Ivacaftor treatment can be reached by co-supplementation of genistein, as suggested by their highly synergistic action in intestinal organoidsOur secondary objectives…

A randomized, double-blind, double-dummy, activecontrolled, 3-period complete cross-over study to assess the bronchodilator effect and safety of two doses of QVM149 compared to a fixed dose combination of salmeterol/fluticasone in patients with asthma.

To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 *g o.d. and 150/50/80 *g o.d. compared to a FDC ofsalmeterol/fluticasone at a dose of 50/500 *g b.i.d. after 3 weeks of treatment in patients with asthma.

A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

The primary objective of the study is to assess the efficacy and safety of 3 different treatment arms (bevacizumab alone, atezolizumab-bevacizumab combination with acetylsalicylic acid and atezolizumab-bevacizumab combination with placebo) in…

Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease

The primary objective is to determine the time until maximum effect is reached of inhaled levodopa on motor function of Parkinson's disease patients during an off period. The secondary objectives are to determine the clinical improvement of…